Citation Impact
Citing Papers
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
The ɛ-(γ-Glutamyl)Lysine Crosslink and the Catalytic Role of Transglutaminases
1977
Human endothelial cell growth on mussel-inspired nanofiber scaffold for vascular tissue engineering
2010
TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION
1988
Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death
2006 Standout
Clinical translation of angiogenesis inhibitors
2002 Standout
Modulation of the fibrinolytic system by major peripheral ischemia
1994
Actions and interactions of high pressure and general anaesthetics
1988
Tissue-type plasminogen activator, type 1 plasminogen activator inhibitor and their complex in plasma with disseminated intravascular coagulation
1992
Time Course of Hemostatic Abnormalities in Sepsis and its Relation to Outcome
1993
Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma
1988 StandoutNobel
Propagation, rethrombosis and new thrombus formation after acute deep venous thrombosis
1995
Binding of tissue plasminogen activator to cultured human endothelial cells.
1987
Angiogenesis: an organizing principle for drug discovery?
2007 Standout
Changes of the hemostatic network in critically ill patients-Is there a difference between sepsis, trauma, and neurosurgery patients?
2000
Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis
1991
Molecular and cellular mechanisms of general anaesthesia
1994 StandoutNature
The Fibrinolytic System of the Vessel Wall and Its Role in the Control of Thrombosis
1990
Metabolism of Activated Complement Component C3 Is Mediated by the Low Density Lipoprotein Receptor-related Protein/α2-Macroglobulin Receptor
1999
Tissue Plasminogen Activator Contributes to the Late Phase of LTP and to Synaptic Growth in the Hippocampal Mossy Fiber Pathway
1998 StandoutNobel
Fibrinolytic response in normal subjects to venous occlusion and DDAVP infusion
1989
Transglutaminases: crosslinking enzymes with pleiotropic functions
2003 Standout
Coagulation disorders in septic shock
1993
PAI‐1 and atherothrombosis
2005
Resistance to Activated Protein C as a Basis for Venous Thrombosis
1994 Standout
Habitual exercise and arterial aging
2008
Impaired fibrinolysis in coronary artery disease
1988
Prevention and Treatment of Thromboembolic and Ischemic Complications Associated with Endovascular Procedures: Part I???Pathophysiological and Pharmacological Features
2000
Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta.
1991
Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
1991 Standout
Cyclosporine
1989 Standout
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
2001 Standout
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
2002 Standout
Disseminated Intravascular Coagulation
1999 Standout
The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension
1992 Standout
PROTEIN C DEFICIENCY AND PORTAL THROMBOSIS IN LIVER TRANSPLANTATION IN CHILDREN
1988
Stimulatory effect of unsaturated fatty acids on the level of plasminogen activator inhibitor‐1 mRNA in cultured human endothelial cells
1995 StandoutNobel
Biochemical and biological aspects of the plasminogen activation system
1990
The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina
1994 Standout
The pathogenesis of atherosclerosis: a perspective for the 1990s
1993 StandoutNature
Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein.
1990
Plasminogen activator inhibitors
1987
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Development of the human coagulation system in the full-term infant
1987 Standout
Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor.
1984
Protease-activated receptor 1 (PAR1) signalling desensitization is counteracted via PAR4 signalling in human platelets
2011 StandoutNobel
Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
1994 Standout
Maturation of the hemostatic system during childhood
1992 Standout
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
Angiogenesis Research: Guidelines for Translation to Clinical Application
2001
Characterization and fibrinolytic properties of human omental tissue mesothelial cells. Comparison with endothelial cells
1990 Standout
Serpin Structure, Mechanism, and Function
2002 Standout
A Critical Review of the Evidence Supporting a Relationship Between Impaired Fibrinolytic Activity and Venous Thromboembolism
1991
Regulation of the endothelial cell urokinase-type plasminogen activator receptor. Evidence for cyclic AMP-dependent and protein kinase C-dependent pathways.
1993 StandoutNobel
Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.
1987 Standout
Reverse fibrin autography: A method to detect and partially characterize protease inhibitors after sodium dodecyl sulfate-polyacrylamide gel electrophoresis
1984
Bispecific Antibodies as Novel Bioconjugates
1998
Age Dependence of Blood Fibrinolytic Components and the Effects of Low-Dose Oral Contraceptives on Coagulation and Fibrinolysis in Teenagers
1988
THROMBOEMBOLIC COMPLICATIONS AND HAEMOSTATIC CHANGES IN CYCLOSPORIN-TREATED CADAVERIC KIDNEY ALLOGRAFT RECIPIENTS
1985
Insulin Stimulates the Synthesis of Plasminogen Activator Inhibitor 1 by the Human Hepatocellular Cell Line Hep G2
1988
Plasminogen Activators, Tissue Degradation, and Cancer
1985 Standout
Spontaneous fibrinolysis in whole human plasma. Identification of tissue activator-related protein as the major plasminogen activator causing spontaneous activity in vitro.
1985
Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response.
1989
Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator
1984
A moderate fish intake increases plasminogen activator inhibitor type-1 in human volunteers
1989
Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma
1984
Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension.
1990
Factors contributing to increased vascular fibrinolytic activity in mongrel dogs.
1993
DEFICIENCIES OF PROTEIN C, AN INHIBITOR OF BLOOD COAGULATION
1982
Neonatal antithrombin III
1984
The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator
1990 StandoutNobel
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
Spontaneous lysis of deep venous thrombi: rate and outcome
1989
Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.
1993 Standout
Polydopamine and Its Derivative Materials: Synthesis and Promising Applications in Energy, Environmental, and Biomedical Fields
2014 Standout
Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells.
1990 StandoutNobel
Subcutaneous and Visceral Adipose Tissue: Their Relation to the Metabolic Syndrome
2000 Standout
The Dendritic Cell Receptor for Endocytosis, Dec-205, Can Recycle and Enhance Antigen Presentation via Major Histocompatibility Complex Class II–Positive Lysosomal Compartments
2000 StandoutNobel
Chronic Thromboembolic Pulmonary Hypertension
2006 Standout
Urokinase-related proteins in human urine. Isolation and characterization of single-chain urokinase (pro-urokinase) and urokinase-inhibitor complex.
1986
Detection and partial characterization of an inhibitor of plasminogen activator in human platelets.
1984
Investigation of Chronic Venous Insufficiency
2000 Standout
Posttranslational processing of the LDL receptor and its genetic disruption in familial hypercholesterolemia
1982 StandoutNobel
Plasminogen receptors, urokinase receptors, and their modulation on human endothelial cells
1988
Deep venous insufficiency: The relationship between lysis and subsequent reflux
1993
Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium.
1988 Standout
Low-affinity heparin stimulates the inactivation of plasminogen activator inhibitor-1 by thrombin
1994
Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis
2016 Standout
EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION
1986 Standout
Endothelial cells in physiology and in the pathophysiology of vascular disorders.
1998 Standout
Tumors: Wounds That Do Not Heal
1986 Standout
Multiple event activation of a generic prodrug trigger by antibody catalysis
1999 StandoutNobel
Thrombolysis with Human Extrinsic (Tissue-Type) Plasminogen Activator in Rabbits with Experimental Jugular Vein Thrombosis. EFFECT OF MOLECULAR FORM AND DOSE OF ACTIVATOR, AGE OF THE THROMBUS, AND ROUTE OF ADMINISTRATION
1983
Thromboembolic Disease – Critical Evaluation of Laboratory Investigation
1992
RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION
1985
Fibrinolytic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients With Angina Pectoris
1996
Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.
1987 Standout
Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells.
1984 Standout
The role of fragment X polymers in the fibrin enhancement of tissue plasminogen activator-catalyzed plasmin formation.
1990 StandoutNobel
High‐affinity binding sites for human Glu‐plasminogen unveiled by limited plasmic degradation of human fibrin
1986
C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged Men
1999 Standout
Endothelial Function and Dysfunction
2007 Standout
Works of D Collen being referenced
Endothelium in hemostasis and thrombosis
1997
Metabolism of Fibrinogen in Cirrhosis of the Liver
1971
Thrombin-Antithrombin Iii and Plasmin-Antiplasmin Complexes as Indicators of in Vivo Activation of the Coagulation and/or Fibrinolytic Systems
1977
The presence and release of alpha 2-antiplasmin from human platelets
1981
Introduction
1993
Requirement of heparin for arterial and venous thrombolysis with recombinant tissue-type plasminogen activator
1991
Tissue‐type Plasminogen Activator
2008
Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay.
1983
Protease inhibitors of human plasma. Alpha-2-antiplasmin.
1985
Fibrinolysis and Coagulation in Patients with Infectious Disease and Sepsis
1991
Influence of Hydrostatic Pressure on the Reversible Polymerization of Fibrin Monomers
1970 Nature
Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits
1989
Complexes between tissue-type plasminogen activator and proteinase inhibitors in human plasma, identified with an immunoradiometric assay.
1983
Deficient t-PA Release and Elevated PA Inhibitor Levels in Patients with Spontaneous or Recurrent Deep Venous Thrombosis
1987
Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons
1992
Increased PA-Inhibitor Levels in the Postoperative Period – No Cause-Effect Relation with Increased Cortisol
1985
Coronary thrombolysis with tissue-type plasminogen activator: an overview
1985